ZYLORIC

This brand name is authorized in Austria, Brazil, Cyprus, France, Hong Kong SAR China, Ireland, Italy, Japan, Malta, Netherlands, Singapore, Spain, UK.

Active ingredients

The drug ZYLORIC contains one active pharmaceutical ingredient (API):

1	Allopurinol UNII 63CZ7GJN5I - ALLOPURINOL
	Allopurinol is a xanthine-oxidase inhibitor. Allopurinol and its main metabolite oxipurinol lower the level of uric acid in plasma and urine by inhibition of xanthine oxidase, the enzyme catalyzing the oxidation of hypoxanthine to xanthine and xanthine to uric acid.
	Read more about Allopurinol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ZYLORIC Tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M04AA01	Allopurinol	M Musculo-skeletal system → M04 Antigout preparations → M04A Antigout preparations → M04AA Preparations inhibiting uric acid production
Discover more medicines within M04AA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	505609601116310, 505609602112319
ES	Centro de información online de medicamentos de la AEMPS	43775, 56360
FR	Base de données publique des médicaments	60470499, 62949893, 64148136
GB	Medicines & Healthcare Products Regulatory Agency	14419, 14469, 147468, 147470, 164548
HK	Department of Health Drug Office	03779, 10041
IE	Health Products Regulatory Authority	52884, 55700
IT	Agenzia del Farmaco	021259015, 021259027
JP	医薬品医療機器総合機構	3943001F1314, 3943001F2027
MT	Medicines Authority	MA955/00601, MA955/00602, PI908/20801A, PI908/20802A
NL	Z-Index G-Standaard, PRK	25135, 3913, 671
SG	Health Sciences Authority	06060P, 06061P